Cyclophosphamide and pembrolizumab for advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 3 or stage 4 melanoma that cannot be removed by surgery and is not in the eye or uvea.
- You have tried a PD-1 or PD-L1 immunotherapy before, and your cancer got worse while on it.
- You are at least 18 years old and able to care for yourself (ECOG score 0-2).
- Your overall health—including kidney, liver, and blood counts—is adequate based on standard tests.
- If you have had brain metastases, they must be treated and stable for at least 28 days, and you must be on a low stable dose of steroids.
- You must agree to use effective birth control if you or your partner could become pregnant, and not donate sperm during the study and for a period after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new experimental drug, BI-1808, alone or with an approved cancer drug called pembrolizumab (Keytruda). It's for people with advanced cancers that have stopped responding to standard treatments.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial tests whether injecting immune-boosting drugs directly into melanoma tumors, alongside the immunotherapy pembrolizumab, can help people whose cancer has not responded to previous immunotherapy. It aims to shrink tumors and improve treatment outcomes.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a combination of immunotherapy treatments for advanced melanoma that has not responded to standard therapy. The goal is to use your own immune cells to fight the cancer more effectively.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.